Article Text

PDF
Seroprevalence and awareness of human papillomavirus infection and cervical cancer screening results among reproductive-aged Georgian women
  1. Maia Butsashvili1,
  2. Tinatin Abzianidze2,
  3. Maia Kajaia3,
  4. Dodo Agladze4,
  5. Ekaterine Kldiashvili5,
  6. Robert Bednarczyk6,
  7. Louise-Anne McNutt7,
  8. George Kamkamidze8
  1. 1Director, Health Research Union (HRU), Tbilisi, Georgia
  2. 2Epidemiologist, Health Research Union (HRU), Tbilisi, Georgia
  3. 3Head of Epidemiologic Department, Health Research Union (HRU), Tbilisi, Georgia
  4. 4Laboratory Scientist, Health Research Union (HRU), Tbilisi, Georgia
  5. 5Laboratory Scientist, Health Research Union (HRU), Tbilisi, Georgia
  6. 6Associate Professor, Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
  7. 7Associate Professor of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, Albany, NY, USA
  8. 8Head of Laboratory Department, Health Research Union (HRU), Tbilisi, Georgia
  1. Correspondence to Dr Maia Kajaia, Health Research Union, 8 Nutsubidze Str., Tbilisi 0177, Georgia; maiakajaia{at}yahoo.com

Abstract

Introduction As is the case in many developing countries, more than half of the new cervical cancer cases in Georgia are late-stage diagnoses, thus reducing the opportunity for effective treatment. A state cancer screening programme was launched in Tbilisi in 2006; 5 years later the programme had expanded to other regions in Georgia.

Methods This study was designed to estimate awareness about human papillomavirus (HPV), cervical cancer screening, the HPV vaccine, and the seroprevalence of HPV infection among reproductive-aged Georgian women. Study participants were recruited from four women's consultation centres in different regions of Georgia. Data were collected through interviewer-administered questionnaires and HPV seroprevalence was assessed for HPV types 6/11/16/18.

Results Of the 500 study participants, 52.0% were aware of HPV and 36.4% stated that the main cause of cervical cancer is HPV. Of those aware of HPV, 78% reported attending for cervical cancer screening at least once during their lifetime. Half (50.8%) of all respondents were unaware of the HPV vaccine. Of the women who agreed to be tested for anti-HPV antibodies (n=317), 21.1% were positive. Women reporting no condom use were more likely to have HPV antibodies (prevalence ratio 2.77; 95% confidence interval 1.79–4.27). Awareness of cervical cancer screening was significantly associated with HPV seropositivity. With multivariate analysis, both absence of condom use and lack of knowledge about cervical cancer screening were independently associated with HPV seropositivity.

Conclusion More comprehensive public awareness campaigns should be developed to raise awareness about HPV screening and prevention.

  • human papillomavirus
  • cervical cancer screening
  • seroprevalence
  • vaccine
  • awareness

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Highlights from this issue
    British Medical Journal Publishing Group